Review Deciphering the Anticancer Efficacy of Oroxylin A Targeting Dysregulated Oncogenes.

IF 3.3 4区医学 Q2 GENETICS & HEREDITY

Current gene therapy Pub Date : 2025-07-09 DOI:10.2174/0115665232362866250625123624

Pratibha Pandey, Subbulakshmi Ganesan, Sumit Rajotiya, Seema Devi, Lalji Baldaniya, M Ravi Kumar, Sorabh Lakhanpal, Shivam Pandey, Meenakshi Verma, Seema Ramniwas, Fahad Khan

{"title":"Review Deciphering the Anticancer Efficacy of Oroxylin A Targeting Dysregulated Oncogenes.","authors":"Pratibha Pandey, Subbulakshmi Ganesan, Sumit Rajotiya, Seema Devi, Lalji Baldaniya, M Ravi Kumar, Sorabh Lakhanpal, Shivam Pandey, Meenakshi Verma, Seema Ramniwas, Fahad Khan","doi":"10.2174/0115665232362866250625123624","DOIUrl":null,"url":null,"abstract":"<p><p>Flavonoids exhibit anti-tumor properties against many human cancer cells, indicating their potential as effective anticancer medicines. Oroxylin A (OrA) is a monoflavonoid molecule that shows significant promise against several types of cancer and possesses a substantial anticancer impact while causing minimal harm to normal tissue. Limited studies have provided a systematic review deciphering the role of oroxylin A in combating breast carcinoma. Hence, we thoroughly analyzed existing research to report various mechanism by which OrA impedes tumor advancement in breast carcinoma, including autophagy, cell cycle arrest, angiogenesis suppression, apoptosis, and glycolysis inhibition. We collected several significant research related to the anticancer potential of oroxylin A and demonstrated anticancerous potential of OrA and its specific mode of action in several human carcinomas. Additionally, we have also incorporated several studies to decipher the structure, bioavailability, and anti-breast cancer potential of Oroxylin A in breast cancer. Overall, this review supports the potential of oroxylin A for developing better anti breast cancer therapeutic approach.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232362866250625123624","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Flavonoids exhibit anti-tumor properties against many human cancer cells, indicating their potential as effective anticancer medicines. Oroxylin A (OrA) is a monoflavonoid molecule that shows significant promise against several types of cancer and possesses a substantial anticancer impact while causing minimal harm to normal tissue. Limited studies have provided a systematic review deciphering the role of oroxylin A in combating breast carcinoma. Hence, we thoroughly analyzed existing research to report various mechanism by which OrA impedes tumor advancement in breast carcinoma, including autophagy, cell cycle arrest, angiogenesis suppression, apoptosis, and glycolysis inhibition. We collected several significant research related to the anticancer potential of oroxylin A and demonstrated anticancerous potential of OrA and its specific mode of action in several human carcinomas. Additionally, we have also incorporated several studies to decipher the structure, bioavailability, and anti-breast cancer potential of Oroxylin A in breast cancer. Overall, this review supports the potential of oroxylin A for developing better anti breast cancer therapeutic approach.

查看原文本刊更多论文

Oroxylin A靶向失调癌基因抗癌疗效的研究综述。

黄酮类化合物对许多人类癌细胞具有抗肿瘤特性，表明其作为有效抗癌药物的潜力。Oroxylin A （OrA）是一种单类黄酮分子，对几种类型的癌症显示出重大的希望，并具有实质性的抗癌作用，同时对正常组织造成最小的伤害。有限的研究提供了一个系统的回顾，解读oroxylin a在对抗乳腺癌中的作用。因此，我们深入分析了现有研究，报道了OrA在乳腺癌中阻碍肿瘤进展的各种机制，包括自噬、细胞周期阻滞、血管生成抑制、细胞凋亡和糖酵解抑制。我们收集了一些与oroxylin A的抗癌潜力相关的重要研究，并证明了oroxylin A的抗癌潜力及其在几种人类癌症中的特定作用模式。此外，我们还结合了几项研究来破译Oroxylin A在乳腺癌中的结构、生物利用度和抗乳腺癌潜力。总之，本综述支持oroxylin A开发更好的抗乳腺癌治疗方法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current gene therapy 医学-遗传学

CiteScore

6.70

自引率

2.80%

发文量

期刊介绍： Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases. Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.